In the wake of the increase in Current Liabilities in the second quarter 2025, Quick Ratio fell to 1.96 a new company low.

Within Biotechnology & Pharmaceuticals industry 45 other companies have achieved higher Quick Ratio than Vigil Neuroscience Inc in second quarter 2025. While Quick Ratio total ranking has improved so far during the Q2 2025 to 470, from total ranking in the first quarter 2025 at 773.

Explain Quick Ratio?
How much Cash & cash equivalents VIGL�s has?
What are VIGL�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VIGL Quick Ratio	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3	(Jun 30 2024) Q2
Y / Y Current Liabilities Change	217.17 %	-52.45 %	192.83 %	201.18 %	31.69 %
Y / Y Cash & cash equivalent Change	-22.72 %	-14.31 %	-17.08 %	-16.74 %	-42.28 %
Quick Ratio MRQ	1.96	21.29	2.86	3.64	8.06
VIGL's Total Ranking	# 470	# 773	# 739	# 361	#
Seq. Current Liabilities Change	733.83 %	-88.02 %	11.79 %	184.02 %	25.01 %
Seq. Cash & cash equivalent Change	-23.1 %	-10.93 %	-12.11 %	28.38 %	-14.73 %

Quick Ratio second quarter 2025 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 46
Healthcare Sector	# 209
Overall Market	# 470

Quick Ratio Statistics
High	Average	Low
96.09	24.6	1.96
(Dec 31 2022)		(Jun 30 2025)

Financial Statements
Vigil Neuroscience Inc 's Current Liabilities	$ 34 Millions	Visit VIGL's Balance sheet
Vigil Neuroscience Inc 's Cash & cash equivalent	$ 67 Millions	Visit VIGL's Balance sheet
Source of VIGL's Sales		Visit VIGL's Sales by Geography

Cumulative Vigil Neuroscience Inc 's Quick Ratio

VIGL's Quick Ratio for the trailling 12 Months

VIGL Quick Ratio	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months
Y / Y Current Liabilities TTM Growth	149.98 %	106.2 %	124.97 %	122.72 %	107.22 %
Y / Y Cash & cash equivalent TTM Growth	-17.45 %	-23.95 %	-29.82 %	-34.24 %	-37.61 %
Quick Ratio TTM	3.53	4.81	4.73	6.78	10.69
Total Ranking TTM	# 3052	# 3408	# 3192	# 3009	#
Seq. Current Liabilities TTM Growth	29.37 %	-5.37 %	36.52 %	49.57 %	6.71 %
Seq. Cash & cash equivalent TTM Growth	-5.14 %	-3.66 %	-4.82 %	-5.09 %	-12.61 %

Quick ratio ranking by company, industry and sector >> Back to VIGL Financial Strength Comparisons >> Go to Compare VIGL Quick Ratio to its Competitors

News about Vigil Neuroscience Inc Quick Ratio

Vigil Neuroscience's Strategic Investment from Sanofi Raises Questions about Financial Health

In a recent press release, Vigil Neuroscience Inc. announced a significant strategic investment from Sanofi, amounting to $40 million. The investment was made at an as-converted price of $7.44 per share of common stock. While this news may initially seem promising for Vigil Neuroscience, a closer examination of the company s financial situation raises questions.
Notably, the increase in Current Liabilities during the third quarter of 2023 had a direct impact on the Quick Ratio, which fell to 13.18, marking a new company low. To put these numbers into perspective, it is worth highlighting that 28 other companies within the industry reported higher Quick Ratios during the same period. This decline signifies that Vigil Neuroscience now ranks lower at 205 compared to 18.39 in the previous quarter.
Furthermore, when comparing the trailing twelve months Quick Ratio, it becomes evident that the growth in Current Liabilities during the third quarter of 2023 to $10.142 million led to a cumulative Quick Ratio decrease to 22.97. Although this figure still surpasses the company s trailing twelve months average Quick Ratio, it falls short when compared to 162 other industry companies that achieved superior figures within the same period.

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2025 to $34.11 millions, cumulative Quick Ratio decreased to 3.53 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Vigil Neuroscience Inc . While Quick Ratio overall ranking has improved so far to 3052, from total ranking during the twelve months ending first quarter 2025 at 3408.

Explain Quick Ratio?
How much Cash & cash equivalents VIGL�s has?
What are VIGL�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 143
Healthcare Sector	# 841
Within the Market	# 3052

trailing twelve months Quick Ratio Statistics
High	Average	Low
20.19	13.02	3.31
(Dec 31 2022)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2025 MRQ Cash & cash equivalent	Jun 30 2025 MRQ Current Liabilities
Compugen Ltd	5.31	$ 93.877 Millions	$ 17.691 Millions
Immunocore Holdings Plc	5.27	$ 882.811 Millions	$ 167.641 Millions
Atyr Pharma Inc	5.17	$ 80.346 Millions	$ 15.531 Millions
Inhibrx Biosciences Inc	5.07	$ 186.567 Millions	$ 36.770 Millions
Vaxcyte Inc	4.82	$ 306.744 Millions	$ 63.628 Millions
Cabaletta Bio Inc	4.69	$ 194.682 Millions	$ 41.540 Millions
Agomab Therapeutics Nv	4.65	$ 96.788 Millions	$ 20.820 Millions
Precision Biosciences Inc	4.59	$ 62.242 Millions	$ 13.568 Millions
Cardiff Oncology Inc	4.45	$ 70.957 Millions	$ 15.948 Millions
Fennec Pharmaceuticals Inc	4.45	$ 37.410 Millions	$ 8.414 Millions
Vivosim Labs Inc	4.23	$ 9.055 Millions	$ 2.142 Millions
Lineage Cell Therapeutics Inc	3.93	$ 42.288 Millions	$ 10.756 Millions
Inmune Bio Inc	3.89	$ 33.374 Millions	$ 8.586 Millions
Cardiol Therapeutics inc	3.79	$ 16.405 Millions	$ 4.332 Millions
Arcellx Inc	3.72	$ 453.103 Millions	$ 121.850 Millions
Alector Inc	3.64	$ 307.280 Millions	$ 84.354 Millions
Lenz Therapeutics Inc	3.62	$ 37.608 Millions	$ 10.398 Millions
Biontech Se	3.61	$ 8,655.360 Millions	$ 2,399.376 Millions
Relay Therapeutics Inc	3.50	$ 113.941 Millions	$ 32.525 Millions
Vor Biopharma Inc	3.41	$ 200.565 Millions	$ 58.773 Millions
Kodiak Sciences Inc	3.36	$ 104.165 Millions	$ 31.011 Millions
Moderna Inc	3.26	$ 5,131.000 Millions	$ 1,572.000 Millions
Recursion Pharmaceuticals Inc	3.20	$ 525.110 Millions	$ 164.026 Millions
Turnstone Biologics Corp	3.13	$ 18.594 Millions	$ 5.934 Millions
Immunitybio inc	3.03	$ 153.658 Millions	$ 50.644 Millions
Passage Bio Inc	2.91	$ 57.626 Millions	$ 19.801 Millions
Prime Medicine Inc	2.88	$ 98.343 Millions	$ 34.109 Millions
Twist Bioscience Corporation	2.88	$ 250.798 Millions	$ 87.070 Millions
Vericel Corporation	2.84	$ 116.881 Millions	$ 41.132 Millions
Sutro Biopharma Inc	2.76	$ 205.131 Millions	$ 74.246 Millions

Date modified: 2026-09-26T07:41:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.